SLC5A2 and diabetes mellitus: The 2019 ESC-EASD guidelines on diabetes recommend DPP4i administration only when HbA1c targets are not reached after therapy with SGLT-2 inhibitors, metformin and/or GLP-1 receptor agonists [10].